本文へ移動
cccskills
無料GitHub で公開

endo-pa-mra-titrate-renin

In patients with primary aldosteronism receiving mineralocorticoid receptor antagonist therapy, the guideline recommends titrating the MRA dose upward to raise renin when blood pressure remains uncontrolled and renin is suppressed. Consider this step when hypertension is not at goal despite MRA therapy and plasma renin activity (or direct renin concentration) is low.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.5 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Titrate MRA dose to raise renin in PA patients with uncontrolled hypertension

STEP 1 — Gather Information

Confirm primary aldosteronism diagnosis, current MRA type and dose, seated morning blood pressure, plasma renin activity (PRA) or direct renin concentration (DRC), serum potassium, and estimated glomerular filtration rate (eGFR). Document these values to assess whether hypertension is uncontrolled and renin is suppressed.

STEP 2 — Rule In / Rule Out

If blood pressure is above target (e.g., ≥130/80 mmHg) AND renin is suppressed (PRA <0.5 ng/mL/h or DRC <4 mU/L), proceed to Step 3; otherwise, evaluate medication adherence, lifestyle factors, or consider adding other antihypertensive agents before increasing MRA dose.

STEP 3 — Classify or Stratify

Estimate the MRA dose increase based on current renin level: if renin is very low (PRA <0.2 ng/mL/h or DRC <2 mU/L), plan to increase spironolactone by 25–50 mg/day; if renin is low but detectable (PRA 0.2–0.5 ng/mL/h or DRC 2–4 mU/L), plan to increase by 25 mg/day; for eplerenone, use equivalent potency increments. Calculate the specific dose increment and prepare the new prescription.

STEP 4 — Decide

Increase the MRA dose as calculated, counsel the patient on adherence and dietary sodium restriction, and schedule reassessment of blood pressure and renin in 8–12 weeks.

Clinical Guardrails / Mimics / Pitfalls

Do not increase MRA if blood pressure is already at target; avoid doses that risk hyperkalemia (monitor K+ and creatinine); do not rely on renin rise alone if BP remains uncontrolled—add other agents; be cautious in CKD where renin response may be blunted.

Concrete Clinical Example

A 60-year-old woman with bilateral PA on spironolactone 50 mg daily presents with BP 148/92 mmHg, PRA 0.15 ng/mL/h, K+ 4.6 mmol/L, eGFR 68 mL/min/1.73m². Increase spironolactone to 75 mg daily and recheck BP and renin in 10 weeks.

Source: Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, DOI: 10.1210/clinem/dgaf284

TODO: consider adding scripts/calc.py for the endo-pa-mra-titrate-renin calculator

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する